Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$29.92
+1.2%
$28.62
$11.64
$39.71
$475.35M1.08104,294 shs11,497 shs
Omeros Corporation stock logo
OMER
Omeros
$14.67
-0.7%
$11.87
$2.95
$17.65
$1.06B2.661.41 million shs107,544 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$24.60
-0.8%
$23.34
$18.80
$27.64
$972.54M0.32808,277 shs60,685 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$12.18
+4.6%
$11.10
$9.23
$28.43
$1.67B0.523.01 million shs857,202 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
+7.96%+9.44%+1.86%+9.24%+109.13%
Omeros Corporation stock logo
OMER
Omeros
-1.93%+0.68%+35.50%+28.32%+116.89%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
+1.43%-2.44%+9.21%+19.87%-3.95%
Perrigo Company plc stock logo
PRGO
Perrigo
-2.67%+0.67%+7.07%-21.18%-53.98%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$29.92
+1.2%
$28.62
$11.64
$39.71
$475.35M1.08104,294 shs11,497 shs
Omeros Corporation stock logo
OMER
Omeros
$14.67
-0.7%
$11.87
$2.95
$17.65
$1.06B2.661.41 million shs107,544 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$24.60
-0.8%
$23.34
$18.80
$27.64
$972.54M0.32808,277 shs60,685 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$12.18
+4.6%
$11.10
$9.23
$28.43
$1.67B0.523.01 million shs857,202 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
+7.96%+9.44%+1.86%+9.24%+109.13%
Omeros Corporation stock logo
OMER
Omeros
-1.93%+0.68%+35.50%+28.32%+116.89%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
+1.43%-2.44%+9.21%+19.87%-3.95%
Perrigo Company plc stock logo
PRGO
Perrigo
-2.67%+0.67%+7.07%-21.18%-53.98%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.57
Moderate Buy$42.7542.90% Upside
Omeros Corporation stock logo
OMER
Omeros
2.83
Moderate Buy$40.33174.94% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.29
Hold$29.4019.54% Upside
Perrigo Company plc stock logo
PRGO
Perrigo
2.00
Hold$19.3358.76% Upside

Current Analyst Ratings Breakdown

Latest ASMB, PRGO, OMER, and PCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Reiterated RatingBuy$50.00
5/1/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Boost Price TargetSector Perform$22.00 ➝ $24.00
5/1/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Boost Price TargetBuy$30.00 ➝ $32.00
4/29/2026
Perrigo Company plc stock logo
PRGO
Perrigo
DowngradeSell (D-)Sell (E+)
4/27/2026
Perrigo Company plc stock logo
PRGO
Perrigo
UpgradeStrong SellHold
4/21/2026
Omeros Corporation stock logo
OMER
Omeros
Reiterated RatingSell (D-)
4/21/2026
Omeros Corporation stock logo
OMER
Omeros
Reiterated RatingBuy$36.00
4/20/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Reiterated RatingSell (D-)
4/7/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
UpgradeStrong SellHold
4/6/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Boost Price TargetBuy$39.00 ➝ $43.00
4/2/2026
Omeros Corporation stock logo
OMER
Omeros
UpgradeHoldStrong-Buy
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$72.30M6.57N/AN/A$13.04 per share2.29
Omeros Corporation stock logo
OMER
Omeros
N/AN/A$1.84 per share7.97($1.71) per shareN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$726.41M1.33$3.84 per share6.40$16.62 per share1.48
Perrigo Company plc stock logo
PRGO
Perrigo
$4.25B0.39$5.66 per share2.15$21.33 per share0.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$6.12M-$0.74N/AN/AN/A-8.47%-5.63%-3.62%5/7/2026 (Estimated)
Omeros Corporation stock logo
OMER
Omeros
-$3.35M-$0.50N/AN/AN/AN/A-72.14%59.71%5/21/2026 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$7.03M$0.12205.9810.47N/A0.70%10.24%5.47%N/A
Perrigo Company plc stock logo
PRGO
Perrigo
-$1.43B-$10.28N/A5.121.34-33.51%9.41%3.97%5/6/2026 (Estimated)

Latest ASMB, PRGO, OMER, and PCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2026Q1 2026
Omeros Corporation stock logo
OMER
Omeros
-$0.3007N/AN/AN/A$10.13 millionN/A
5/7/2026Q1 2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$0.65N/AN/AN/A$9.27 millionN/A
5/6/2026Q1 2026
Perrigo Company plc stock logo
PRGO
Perrigo
$0.3135$0.43+$0.1165-$2.87$1.04 billion$841.80 million
4/30/2026Q1 2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.61$0.60-$0.01$0.07$171.80 million$177.38 million
3/31/2026Q4 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.55$3.14+$3.69$0.98$40.15 millionN/A
3/19/2026Q4 2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$0.51$2.48+$2.99$2.48$7.42 million$42.47 million
2/26/2026Q4 2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.85$0.57-$0.28$0.04$201.93 million$196.87 million
2/26/2026Q4 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.80$0.77-$0.03-$10.22$1.09 billion$1.11 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.169.53%+5.21%N/A 23 Years

Latest ASMB, PRGO, OMER, and PCRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2026
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.2910.29%5/29/20265/29/20266/16/2026
2/19/2026
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.299.36%3/2/20263/2/20263/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
5.22
5.22
Omeros Corporation stock logo
OMER
Omeros
N/A
2.76
2.76
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.56
4.73
3.35
Perrigo Company plc stock logo
PRGO
Perrigo
1.23
2.76
1.63

Institutional Ownership

CompanyInstitutional Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
19.92%
Omeros Corporation stock logo
OMER
Omeros
48.79%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%

Insider Ownership

CompanyInsider Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
5.10%
Omeros Corporation stock logo
OMER
Omeros
12.90%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
Perrigo Company plc stock logo
PRGO
Perrigo
0.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
10015.89 million15.08 millionOptionable
Omeros Corporation stock logo
OMER
Omeros
21072.17 million62.71 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72039.35 million36.82 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,100137.65 million137.10 millionOptionable

Recent News About These Companies

Perrigo: Q1 Earnings Snapshot
Perrigo (PRGO) Projected to Post Earnings on Wednesday
Perrigo Announces Quarterly Dividend
Perrigo: Positioning Through A Thesis Reset

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Assembly Biosciences stock logo

Assembly Biosciences NASDAQ:ASMB

$29.92 +0.37 (+1.24%)
As of 10:52 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Omeros stock logo

Omeros NASDAQ:OMER

$14.67 -0.10 (-0.68%)
As of 10:52 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$24.60 -0.20 (-0.79%)
As of 10:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Perrigo stock logo

Perrigo NYSE:PRGO

$12.18 +0.54 (+4.62%)
As of 10:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.